Richard Pazdur (via AACR)
FDA panel admonishes Merck with a gentle — and rare — slapdown for rushing its pitch on an accelerated OK for adjuvant Keytruda in TNBC
Merck is going to have to wait longer before the FDA considers opening the door to using Keytruda as an adjuvant therapy for high risk …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
